Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.

The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.

Zhitong FinanceJan 10 10:20

China NT Pharma to Shrink 10-Month Loss

MT NewswiresJan 8 18:12

NT PHARMA (01011.HK): It is expected that from January to October, the company will record a net loss attributable to shareholders of 35 million to -37 million yuan.

On January 8th, Gelonghui announced that NT PHARMA (01011.HK) expects to record a net loss attributable to shareholders ranging from 35 million to 37 million yuan for the ten months ending October 31, 2024, whereas approximately 0.153 billion yuan net loss was recorded for the ten months ending October 31, 2023. The expected reduction in net loss during this period is primarily due to: (a) no recording of production and sales in the Chinese Patent Medicine Business ("disposal business," which was previously fully owned by the company and operated by Suzhou Diyi Pharmaceutical Co., Ltd., which was divested by the Group in August 2023.

Gelonghui FinanceJan 8 17:35

According to the profit warning, NT PHARMA (01011.HK) anticipates that its losses for the first ten months of last year narrowed to between 35 million to 37 million yuan.

NT PHARMA (01011.HK) announced that it expects to record a net loss of between 35 million and 37 million yuan (RMB) for the first ten months ending October last year, while in the same period of 2023, the net loss was approximately 0.153 billion yuan. The company stated that the decrease in losses is mainly due to the absence of losses from the production and sales of Chinese Patent Medicine during the period, and that the group incurred a one-time consulting fee of 37.7 million yuan for two consultants in 2023, while the group did not pay any consulting fees last year. (vc/u)~

AASTOCKSJan 8 17:34

NT PHARMA: PROFIT WARNING AND INSIDE INFORMATION ANNOUNCEMENTUPDATE ON FINANCIAL INFORMATION

HKEXJan 8 17:32 · Announcements

Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.

Track the entire lifecycle of the main sector.

cls.cnJan 7 09:20